Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

... a solid foundation for the Company's ongoing obesity development program. In the overall ... weight loss would be a significant advancement in obesity drug development." The combination therapy ... president, corporate development, diabetes and obesity at Amylin Pharmaceuticals. "Our integrated ...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

... that Contrave may be the first treatment for obesity to target these reward centers in the central ... lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical ... regulatory approval for, and effectively treat obesity with, Contrave and Empatic. The inclusion of ...

deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease

... susceptibility to disease later in life. obesity in particular is linked to earlier AAM, and ... known genetic variants linked to overweight and obesity also correlated with earlier AAM. "The ... able to use them to confirm that overweight and obesity is linked to earlier AAM, and to suggest that ...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

... the ability to address a tremendously underserved obesity market. We look forward to the opportunity to ... lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical ... regulatory approval for, and effectively treat obesity with, Contrave and Empatic. The inclusion of ...

Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program

... highest quality NDA and bring Contrave, our lead obesity product candidate, to market expeditiously." ... lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical ... regulatory approval for, and effectively treat obesity with, Contrave. The inclusion of forward-looking ...

Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities

... provide the opportunity to transform diabetes and obesity treatment and position the Company to be cash ... "The significant unmet need in the diabetes and obesity markets provides an opportunity for Amylin's ... Continue growing SYMLIN revenue Complete obesity clinical trials with amylin/leptin analogs and ...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

... (PST) in San Francisco, California. About obesity obesity is a public health crisis, with more than 70 ... stroke, depression and some forms of cancer. obesity results from an energy imbalance associated with ...

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

... for Contrave(R), the Company's lead obesity product candidate now in Phase 3 clinical trials. ... The patent broadly covers methods of treating obesity with combinations of bupropion and naltrexone, ... lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical ...

Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results

... company focused on the treatment of obesity and other central nervous ... combination with other drugs for the treatment of obesity through 2023. The USPTO has also issued U.S. ... at the recent Annual Scientific Meeting of the obesity Society. These included the following: -- ...

Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain

... company focused on the treatment of obesity and other central nervous system-related ... combination with other drugs for the treatment of obesity through 2023. The USPTO has also issued U.S. ... our product candidate pipeline beyond our initial obesity programs by extending into other central nervous ...

Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting

... company focused on the treatment of obesity and other central nervous system-related ... presentations and one sponsored symposium at The obesity Society Annual Scientific Meeting, as well as ... at noteworthy investor conferences. The obesity Society Annual Scientific Meeting, Phoenix ...

Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders

... company focused on the treatment of obesity and other central nervous system-related ... the Company as Senior Vice President and Head of obesity and Metabolic Disorders. Dr. Kim will be leading ... at Orexigen to bring to market our two obesity treatment candidates, Contrave(R) and ....

Genaera Corporation to Present at BIO Business Forum

... treatment of obesity. The panel will discuss the obesity epidemic and review the current landscape of both marketed obesity therapies as well as new drugs in development. "Confronting the obesity Epidemic: The Skinny on Innovative New ...

Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity

... and Lorcaserin Second Study for obesity Management) and BLOOM-DM (Behavioral modification ... of overweight patients and patients with obesity as part of the pivotal trial program for ... stopping criteria. About Obesity obesity affects tens of millions of people in the United ...

New Data Reveal Ethnicity May Play Role in Weight Loss Decisions

... the 2007 Annual Scientific Meeting of NAASO, The obesity Society, adds to the growing body of research ... the associated health risks of overweight and obesity is needed among these populations. The new data ... as FDA- approved drugs. "The rates of obesity among African Americans and Hispanic groups ...

Genaera to Present at Biotech 2007 and BIO InvestorForum

... in a panel session entitled, "Advancing obesity Therapeutics" to be held at Biotech 2007 at the ... is scheduled to participate as part of an obesity panel entitled, "Obesity Management: The Thick ... to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 ...

Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review

... modification and Lorcaserin for Overweight and obesity Management). The BLOOM trial is evaluating the ... heart valves or pulmonary artery pressure. About obesity obesity affects tens of millions of people in the United ...

Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review

... modification and Lorcaserin for Overweight and obesity Management). The BLOOM trial is evaluating the ... heart valves or pulmonary artery pressure. About obesity obesity affects tens of millions of people in the United ...

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

... ghrelin and its receptors opens up new opportunities for the treatment of obesity and eating disorders through the use of ghrelin antagonists to suppress ... million and 61 million Americans are obese, and the worldwide incidence of obesity is increasing by an estimated 1% per year. Alcohol dependence is a ...

Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting

... We are delighted that Qnexa data from our previously reported phase 3 obesity study and our previously reported year-long diabetes study have been ... is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment ...

Arena Pharmaceuticals Announces First Quarter 2009 Financial Results

... data from BLOOM (Behavioral modification and Lorcaserin for Overweight and obesity Management), the first of two pivotal trials evaluating the safety and ... trial, BLOSSOM (Behavioral modification and LOrcaserin Second Study for obesity Management), by the end of September 2009. ...

VIVUS Reports First Quarter 2009 Financial Results and Highlights

... "Our pivotal phase 3 trials for both Qnexa for the treatment of obesity and avanafil for the treatment of erectile dysfunction are proceeding as ... is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment ...

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

... of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), ... and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave or Empatic. The inclusion of forward-looking statements ...

New England Peptide Forms Scientific Advisory Board

... synthesis and development of novel peptide hormones for diabetes, obesity and neuropsychiatric therapies. With more than 20 years of experience in ... life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides' inherent low toxicity and high potency, coupled ...

Amylin Pharmaceuticals Reports Third Quarter Financial Results

... and a DDP-4 inhibitor on a background of metformin therapy. obesity Program -- Completed enrollment of a phase 2B study to evaluate ... for exenatide once weekly and continued investment in the Company's obesity programs. Non-GAAP, research and development expenses net of cost sharing ...

Anthill Technologies Announces Agreement With Zafgen

... Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue. Under the ... capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs. "We are very pleased to have the opportunity to assist ...

Genaera Corporation Announces Second Quarter Financial Results

... costs related to the trodusquemine (MSI-1436) program for the treatment of obesity and type 2 diabetes and increases in stock-based compensation expense. ... (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In ...

OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003

... and ziprasidone. Zonisamide is also a component of the Company's obesity treatment candidate Empatic(TM), which is in the later stages of Phase II ... obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM), ...

Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity

... announced today the receipt of The European Association for the Study of obesity (EASO) poster award at the 16th European Congress on obesity (ECO 2008) May 14-17, 2008 in Geneva, Switzerland. The poster, Mechanism ...

Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO

... i.e., proteomics on the fly." A major bottleneck in studying obesity and obesity-related diseases (such as diabetes, heart disease, ... of new tools for protein extraction and analysis, for the study of obesity and obesity-related diseases, or other procedures and diseases; that due ...

Genaera Corporation Announces First Quarter Financial Results

... increases in expenses related to the trodusquemine (MSI-1436) program for obesity and type 2 diabetes and a net increase in indirect expenses due to an ... (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In ...

JCI table of contents: April 22, 2008

... NEPHROLOGY: Connecting the dots between obesity and kidney disease Individuals who are obese have a greater risk of ... Medical College, Philadelphia, have outlined a mechanism by which obesity can cause a clinical condition that is an indicator of kidney damage ...

Genaera Corporation Announces 2007 Financial Results

... on two core programs, MSI-1436 for the treatment of type 2 diabetes and obesity being developed internally, and MEDI-528 for the treatment of asthma being ... (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In ...

Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial

... of triglycerides, a significant source of calories in the diet. Given that obesity is a major and growing health concern, we believe SLx-4090's potential to ... of high density lipoprotein (HDL) and/or high triglyceride levels. obesity is a substantial and growing problem in the US and in the rest of the ...

FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children

... high blood pressure(1); increase in pediatric cases linked to growing obesity epidemic(2,3) - Diovan has a proven safety ... Heart Association Committee on Atherosclerosis, Hypertension, and obesity in Youth of the Council on Cardiovascular Disease in the Young, ...

Nastech Announces Third Quarter 2007 Financial Results

... deferred revenue from Merck & Co., Inc. related to our PYY(3-36) obesity program, a $7.0 million milestone payment and reimbursement revenue ... * Initiated a Phase 2 clinical trial for PYY(3-36) Nasal Spray for obesity * Initiated a Phase 2 clinical trial for Insulin Nasal Spray for ...

Amylin Pharmaceuticals Reports Third Quarter Financial Results

... exenatide long-acting release program and our integrated neurohormone obesity program." Quarter ended September 30, 2007 Net product sales of $177.4 ... LAR and ongoing costs associated with the advancement of the Company's obesity development programs. Collaborative profit sharing, which represents ...

Enzyme promotes fat formation

... The enzyme TPPII may contribute to obesity by stimulating the formation of fat cells, suggests a study in EMBO ... that 12 million adults in the UK will be obese by 2010 if nothing is done. obesity is responsible for 70% of cardiovascular diseases and 80% of type II ...

Genaera Elects New Board Member and Announces Executive Appointments

... focus on the trodusquemine (MSI-1436) clinical development program in obesity and type 2 diabetes. About Genaera Genaera Corporation is focused on ... (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In ...

Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference

... on the development of pharmaceutical product candidates for the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010, and ...